Stock · CI · Healthcare
United States · Large Cap · listed since 1982 · Revenue 12 mo. $282.4B
Price as of 11/06/2026
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States.
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Original text from the data provider
Summary
50.7 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
Required FCF growth per year
no growth
no growth afterwards
Price to operating cash flow 7.5×, within its usual range.
Middle half of 20 quarters: 7.5× to 10.1×, median 8.8×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q2 2026
6 more unchanged: Revenue, 12 mo., EBIT margin, FCF margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 14.28% | 11.52% | Rank 62 |
| Return on capital (Greenblatt) | 250.04% | 32.55% | Rank 98 |
| EBIT margin | 3.32% | 18.31% | Rank 11 |
| FCF margin | 3.05% | 14.12% | Rank 14 |
| Gross margin | 9.45% | 60.99% | Rank 3 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 11.26% | 8.04% | Rank 68 |
| Earnings growth, 3 years per year | 1.51% | 5.44% | Rank 39 |
| Earnings growth, 5 years per year | −0.49% | 7.00% | Rank 30 |
| Sustainable growth (ROE × retained earnings) | 0.44% | 3.66% | Rank 9 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 7.63% | 2.90% | Rank 95 |
| FCF yield | 11.03% | 3.63% | Rank 95 |
| EV/saleslower is better | 0.36 | 4.03 | Rank 94 |
| EV/EBITlower is better | 10.93 | 21.73 | Rank 92 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 4.91% | 8.66% | Rank 49 |
| Share price, 6 months | 2.40% | 24.27% | Rank 18 |
| Share price, 3 months | 9.06% | 15.42% | Rank 32 |
| Distance from 52-week high | −7.06% | −7.35% | Rank 51 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 0.49% | 0.30% | Rank 47 |
| Change in share countlower is better | −6.10% | 0.00% | Rank 98 |
| Dividend streak in years | 20 | 10 | Rank 84 |
| Price reaction to results, market-adjusted | −4.88% | 0.05% | Rank 13 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 26.41% | 48.40% | Rank 15 |
| Net debt/EBITDAlower is better | 2.02 | 1.11 | Rank 29 |
| Debt to equitylower is better | 0.75 | 0.48 | Rank 32 |
| Volatility, 1 yearlower is better | 26.97% | 31.42% | Rank 79 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 39.8 | 7.8% | 3.6 | 260M | 1.8 |
| 2017 | 41.8 | 9.4% | 3.6 | 244M | 2.5 |
| 2018 | 48.7 | 8.6% | 3.2 | 247M | 38.6 |
| 2019 | 153.6 | 5.3% | 8.4 | 380M | 33.4 |
| 2020 | 160.4 | 5.1% | 9.3 | 368M | 23.4 |
| 2021 | 174.1 | 4.6% | 6.0 | 341M | 29.2 |
| 2022 | 180.5 | 4.7% | 7.4 | 313M | 25.6 |
| 2023 | 195.3 | 4.4% | 10.2 | 297M | 23.1 |
| 2024 | 247.1 | 3.8% | 9.0 | 283M | 24.4 |
| 2025 | 275.0 | 3.3% | 8.4 | 266M | 23.8 |
3 of 7 StockScorer Score rules met · How the score is built
The Cigna Group mainly meets criteria in the Valuation category. Result from 18 strategies checked.
The Cigna Group is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for The Cigna Group.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 13.1 | 30.0 |
| P/B ratio | 1.9 | 4.8 |
| Return on equity (ROE) | 14.3% | 11.5% |
| Equity ratio | 26.4% | 48.4% |
| Debt-to-equity (D/E) | 0.75 | 0.48 |
| Dividend yield | 2.1% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| CI | The Cigna Groupthis page | |
| ELV | Elevance Health Inc | Low3.6 |
| HUM | Humana Inc | Low2.7 |
| CVS | CVS Health Corp | Low3.6 |
| CNC | Centene Corp | locked |
| UNH | UnitedHealth Group Incorporated | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.